Oculis (NASDAQ:OCS) Reaches New 12-Month Low – Time to Sell?

Posted by Brian Himes on Oct 4th, 2026

Oculis Holding AG (NASDAQ:OCS – Get Free Report) hit a new 52-week low during trading on Friday. The stock traded as low as $8.67 and last traded at $8.76, with a volume of 577748 shares traded. The stock had previously closed at $9.34.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OCS. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright increased their price target on shares of Oculis from $26.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, September 18th. JPMorgan Chase & Co. dropped their price objective on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oculis presently has an average rating of “Moderate Buy” and a consensus target price of $39.44.

View Our Latest Stock Analysis on OCS

Oculis Trading Down 0.3%

The stock has a market capitalization of $506.20 million, a P/E ratio of -5.02 and a beta of 0.62. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $11.48 and its two-hundred day moving average price is $17.69.

Oculis (NASDAQ:OCS – Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. The business had revenue of $0.38 million for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. Equities research analysts forecast that Oculis Holding AG will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OCS. Koshinski Asset Management Inc. bought a new stake in shares of Oculis in the 1st quarter valued at about $238,000. Himension Capital Singapore PTE. LTD. bought a new position in Oculis during the 1st quarter worth approximately $503,000. Y Intercept Hong Kong Ltd bought a new position in Oculis during the 1st quarter worth approximately $776,000. Squarepoint Ops LLC increased its stake in Oculis by 326.4% in the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after purchasing an additional 47,158 shares during the period. Finally, Bank of America Corp DE increased its stake in Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock worth $1,855,000 after purchasing an additional 5,813 shares during the period. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

(Get Free Report)

Oculis (NASDAQ: OCS) is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis’ pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.